All GLG News Analyses Filed Under: Ophthalmology

This "fast track" exposure for the LX211 may allow for a new type of uveitis treatment by the end of 2008. the hope is to decrease toxicity, and increase effectivity.

This glaucoma drug efficacy crossover study shows that bimatoprost (Lumigan) from AGN lowers intraocular pressure better than latanoprost (Xalatan) from PFE in a special subset of glaucoma patients (exfoliative glaucoma).  The difference is only 1 mm Hg which may be statistically significant will...

1. Eyelid basal cell carcinoma. 2. Health problem. 3. Early diagnostic and correct surgery treatment. 4. Risk factors and prevention.

1. Exfoliative glaucoma is specillay difficult to treat medically. 2. Prostaglandin. 3. Early surgery. 4. Lesser costs.

AMO issued their recall of their MoisturePlus solution in late May, but are some contact lens patients still unaware and still using this solution?  The answer is YES.

Bayer and Regeneron are moving forward with their Phase 3 Trial called the VIEW involving VEGF Trap for the treatment for choroidal neovascularization in Age Related Macular Degeneration.  The implications are large for a billion dollar market that is currently dominated by Lucentis (DNA).

Vegf trap useful in wet MD Vegf trap will be a proft maker for this indication Vegf trap is also a contender in cancer therapy

- With limited and mostly unpleasant options available to AMD patients (Lucentis, Macugen, Visudyne), it is encouraging to see other drugs nearing market readiness, even if they are also injectables. - Regeneron/Bayer Schering's drug would require less frequent injections than Lucentis, which would...

Bad news merger of AMO and B&L..

Current management is not responsive to my needs as a practitioner, nor my patient's needs. Let someone else try to make a venerable name good again.